Introduction
============

Age-related macular degeneration (AMD) is the leading cause of vision loss in the world. Choroidal neovascularization (CNV) plays the main role in visual deterioration in exudative AMD.[@b1-cia-9-141]--[@b3-cia-9-141] CNV originating from choriocapillaris and invading the retina is the result of ongoing inflammation that is mainly stimulated by vascular endothelial growth factor (VEGF).[@b4-cia-9-141]--[@b6-cia-9-141] Inhibition of VEGF by anti-VEGF agents can improve prognosis in exudative AMD by suppressing angiogenesis and decreasing vascular permeability.[@b7-cia-9-141],[@b8-cia-9-141] Major clinical trials have reported the superior efficacy of ranibizumab, which is a US Food and Drug Administration-approved anti-VEGF agent (Lucentis; Genentech, San Francisco, CA, USA).[@b9-cia-9-141],[@b10-cia-9-141] Thus, intravitreal injection of ranibizumab has become the standard therapy for AMD worldwide.[@b11-cia-9-141] However, there are still controversial issues on the efficiency of ranibizumab and visual outcome. The delay between the onset of symptoms and the timing of the therapy is reported to be in negative correlation with the outcome.[@b6-cia-9-141],[@b12-cia-9-141] In AMD, CNV was found to enlarge at an average of 10 (1--24) μm per day.[@b13-cia-9-141] Although the predictive value of this rate is small, it is important to stress the timing of treatment initiation. The purpose of the current study was to report the 1-year clinical results of intravitreal ranibizumab treatment in patients with exudative AMD, and to evaluate whether early treatment is of predictive value for prognosis of the disease.

Materials and methods
=====================

Medical reports of patients who underwent intravitreal injections of ranibizumab for new-onset exudative AMD between March 2010 and January 2013 at Başkent University School of Medicine Department of Ophthalmology were reviewed retrospectively. This study was approved by the Başkent University Institutional Review Board and Ethics Committee. The following parameters were achieved from patient's chart at baseline and after 12 months: all patients underwent full ophthalmic examination, which included best-corrected visual acuity (BCVA), intraocular pressure, slit-lamp biomicroscopy, and dilated fundus examination. Central retinal thickness (CRT) measurements were done by spectral domain optical coherence tomography (OCT) (RTVue; Optovue, Fremont, CA, USA). Fluorescein angiography was performed at initial diagnosis. In the charts, BCVA was assessed using Snellen visual acuity and it was converted to a logarithm of the minimum angle of resolution (logMAR) value for statistical analysis. BCVA assessments were done by the same clinic staff who recorded the data. All patients were treated with three consecutive monthly intravitreal injections of ranibizumab and followed up for at least 12 months. After three monthly injections, patients were examined monthly, and subsequent injections were performed as needed (pro re nata) for any recurrence. Recurrence was defined as decrease of at least one line in visual acuity, or presence of new macular hemorrhage on CNV and the presence of intraretinal and/or subretinal fluid, and an increase of 50 μm or over in central retinal thickness in OCT scans. Written informed consent was obtained from all patients before administration of the intravitreal ranibizumab. After the eye had been prepared using 5% povidone--iodine, 0.5 mg of ranibizumab was injected via the pars plana. The duration of the disease was quantified according to the patients' history from the very beginning of visual symptoms (visual distortion, changes in vision acuity, or central blurring) to initial presentation. Patients were divided into two groups: group 1 consisted of patients with visual symptoms for less than 1 month, and patients who had visual symptoms for 1--3 months were placed in group 2. Included patients had symptoms for a maximum of 3 months, underwent at least three injections, and completed 1-year follow-up. The exclusion criteria were any previous treatment for CNV and CNV that was not associated with AMD.

Statistical analysis
--------------------

Statistical analysis was performed using the statistical package SPSS version 17.0 (IBM, Armonk, NY, USA). For each continuous variable, normality was checked by Kolmogorov--Smirnov and Shapiro--Wilk tests and by histograms. Comparisons between groups were applied using the Mann--Whitney *U* test for data not normally distributed. Pre- and postinjection changes were analyzed with Wilcoxon and repeated-measures analyses (Greenhouse--Geisser). Values of *P*\<0.05 were considered statistically significant.

Results
=======

A total of 104 eyes of 88 patients were involved in the study; there were 40 eyes in group 1 (16.2±4.8 days, 7--30 days), and 64 eyes in group 2 (53.1±14.2 days, 35--90 days). The mean age of the patients was 68.5±9.6 (50--87) years. There were 43 female (48.9%) and 45 males (51.1%). The follow-up time was 13.7±1.9 (12--19) months. At baseline, the mean logMAR BCVA was 0.45±0.639 (0--3) in group 1 and 1.06±0.687(0--3) in group 2. The mean logMAR BCVA values per group after treatment are shown in [Table 1](#t1-cia-9-141){ref-type="table"}. The increase in VA was statistically significant for the first, third, sixth, ninth, and twelfth months in group 1 and group 2 compared to baseline (*P*\<0.0001). The mean logMAR BCVA improved significantly, from 0.45±0.639 at baseline to 0.08±0.267 at 12 months in group 1, and from 1.06±0.687 at baseline to 0.75±0.563 at 12 months in group 2. The increase in BCVA was statistically significant in group 1 (*P*=0.009). At the final follow-up, BCVA was increased in 56.7% of the eyes and decreased in 14.5% of the eyes. In 30 (28.8%) eyes, visual acuity remained unchanged at 12 months. Baseline mean CRT was 355.13±119.93 (200--775) μm in group 1 and 371.88±91.047 (234--714) μm in group 2. Mean CRT values per group after treatment are shown in [Table 2](#t2-cia-9-141){ref-type="table"}. The decrease in CRT was statistically significant for the third month between group 1 and group 2 compared to baseline (*P*=0.046). Mean CRT decreased significantly, from 355.13±119.93 μm at baseline to 250.85±45.48 μm at 12 months in group 1, and from 371.88±91.047 μm at baseline to 268.61±53.51 μm at 12 months in group 2. The decrease in CRT was statistically significant in group 1 (*P*=0.001). A graphical representation of CRT and BCVA over time is shown in [Figures 1](#f1-cia-9-141){ref-type="fig"} and [2](#f2-cia-9-141){ref-type="fig"}. The mean number of intravitreal ranibizumab injections applied in the 12-month period was 4.32 (range 3--9). The mean number of injections was 4.57±1.4 (3--9) in group 1 and 4.17±0.9 (3--6) in group 2. There was no significant difference between the two groups (*P*=0.092). No inflammation, infection, ocular toxicity signs, or systemic side effects were seen.

Discussion
==========

Several clinical key trials, such as MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD), ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD), and SAILOR (A Study to Evaluate Ranibizumab in Subjects with Choroidal Neovascularization \[CNV\] Secondary to Age-Related Macular Degeneration) have demonstrated the efficacy and safety of ranibizumab injections for the entire spectrum of CNV subtypes.[@b9-cia-9-141]--[@b11-cia-9-141],[@b14-cia-9-141],[@b15-cia-9-141] In the PrONTO (Prospective OCT Study with Lucentis for Neovascular AMD) trial, after the three consecutive monthly intravitreal injections, further injections were administered according to changes in BCVA, OCT, and ophthalmoscopic macula findings.[@b16-cia-9-141],[@b17-cia-9-141] These reinjection criteria were also used in our study. Results of the PrONTO study (mean improvement in BCVA of 9.2 letters, mean 5.6 injections) were comparable with MARINA or ANCHOR, which assumes stabilization and improvement of visual acuity with a decreased number of injections.[@b16-cia-9-141] In our study, a mean of 4.32 (3--9) injections were performed during a 12-month period to achieve recovery of BCVA and CRT parameters. In the PrONTO study, the mean CRT was 394 μm at baseline and 216 μm at 12 months.[@b16-cia-9-141] In our study, mean CRT declined from 365.43±102.87 μm to 261.78±51.09 μm at 12 months. Reduction in CRT was statistically significant in group 1 (*P*=0.001). A shorter duration of visual symptoms (group 1) was correlated with a higher initial and final BCVA (*P*=0.009). Rauch et al reported that CNV with shorter disease duration yielded better visual outcome when compared with eyes with longer duration after two injections per eye at the 6-month follow-up.[@b6-cia-9-141] They particularly reported favorable results in patients with a duration of less than 1 month. Oliver-Fernandez et al reported that 44% of patients lost vision and 15% lost more than three lines of visual acuity in 28 days.[@b12-cia-9-141] Muether et al also stressed the negative effect of delay in treatment on visual outcome in two recent reports.[@b18-cia-9-141],[@b19-cia-9-141] Analysis of our results demonstrates that intravitreal ranibizumab treatment for exudative AMD clearly preserved and improved mean visual acuity in our patients. Shorter duration of AMD, as measured by the subjective duration of visual symptoms, was associated with a better visual outcome after treatment. The retrospective design and the small sample size are perhaps limitations of our study. The duration of the disease was based on the subjective history given by the patients. This is also considered as a shortcoming. However, there is no way to assess objective duration. Our study was designed to retrospectively analyze 1-year clinical results of intravitreal ranibizumab injections in patients with exudative AMD and to stress that early diagnosis and prompt therapy are associated with favorable outcomes. Currently, intravitreal ranibizumab is the gold-standard therapy for exudative AMD. Better baseline visual acuity and early treatment is essential. Patients must be informed about self-awareness of visual symptoms. Prospective randomized studies with larger sample sizes would reveal more predictive results.
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###### 

Mean logarithm of minimum angle of resolution best-corrected visual acuity changes over 12 months of treatment with intravitreal ranibizumab for exudative age-related macular degeneration

  Group                                           Before therapy   After therapy                             
  ----------------------------------------------- ---------------- --------------- ------------ ------------ ------------
  1                                               0.45±0.639       0.15±0.362      0.12±0.335   0.2±0.405    0.08±0.267
  2                                               1.06±0.687       0.78±0.453      0.73±0.479   0.69±0.531   0.75±0.563
  *P*[\*](#tfn1-cia-9-141){ref-type="table-fn"}   \<0.0001         \<0.0001        \<0.0001     \<0.0001     \<0.0001

**Note:**

*P*\<0.05 was considered statistically significant.

###### 

Central retinal thickness (CRT) changes over 12 months of treatment with intravitreal ranibizumab for exudative age-related macular degeneration

  Group                                           Before therapy   After therapy                                 
  ----------------------------------------------- ---------------- --------------- -------------- -------------- --------------
  1                                               355.13±119.93    246.88±57.73    254.3±69.67    256.35±44.78   250.85±45.48
  2                                               371.88±91.047    260.78±62.28    271.88±61.15   279.83±67.62   268.61±53.51
  *P*[\*](#tfn2-cia-9-141){ref-type="table-fn"}   0.204            0.233           0.046          0.074          0.079

**Note:**

*P*\<0.05 was considered statistically significant.
